Contemporary clinical management of oncology patients is increasingly being guided by predictive molecular and phenotypic profiling in order to optimize the use of targeted- and immuno-therapeutics9, e.g., tumor mutational burden (TMB), MMR, PD-1, and PD-L110. This evidence concerns the gene MRC1 and neoplasm.